The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
Hair care & quick commerce shine
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Dr Mohit Bhandari remotely conducted a complex robotic gastrojejunostomy from Perth using the indigenous SSI Mantra Surgical Robotic System
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
Subscribe To Our Newsletter & Stay Updated
